Subtopic Deep Dive
Dengue Vaccine Development
Research Guide
What is Dengue Vaccine Development?
Dengue vaccine development focuses on creating tetravalent vaccines that elicit safe, cross-protective immunity against all four dengue virus serotypes while mitigating antibody-dependent enhancement (ADE) risks.
Key efforts center on phase 3 trials like CYD-TDV, showing 56% efficacy in Asian children (Capeding et al., 2014, 955 citations). Foundational burden estimates reveal 390 million annual infections globally (Bhatt et al., 2013, 9770 citations). Over 10 high-citation papers document urbanization-driven epidemics and flavivirus challenges (Gubler, 2011; Mackenzie et al., 2004).
Why It Matters
Dengue causes 390 million infections yearly, straining health systems in tropics (Bhatt et al., 2013). CYD-TDV's approval marked the first dengue vaccine, reducing hospitalizations by 80% in seropositive children but highlighting ADE risks in seronegatives (Capeding et al., 2014; Simmons et al., 2012). Next-generation vaccines target universal immunity, potentially averting 100 million cases annually amid urban spread (Gubler, 2011).
Key Research Challenges
Antibody-Dependent Enhancement
ADE increases severe disease risk upon secondary infection with heterologous serotypes. CYD-TDV trials showed higher hospitalization rates in seronegative children (Capeding et al., 2014). Balancing tetravalent responses without enhancing infection remains critical (Simmons et al., 2012).
Cross-Serotype Immunity
Achieving durable protection against all four serotypes proves difficult due to antigenic variation. Global burden mapping underscores need for broad efficacy (Bhatt et al., 2013). Urbanization amplifies multi-serotype circulation challenges (Gubler, 2011).
Trial Design in Endemic Areas
Phase 3 trials must account for baseline serostatus and transmission dynamics. Asian pediatric trial revealed serostatus-dependent outcomes (Capeding et al., 2014). Flavivirus resurgence complicates placebo-controlled designs (Mackenzie et al., 2004).
Essential Papers
The global distribution and burden of dengue
Samir Bhatt, Peter W. Gething, Oliver J. Brady et al. · 2013 · Nature · 9.8K citations
Dengue
Cameron P. Simmons, Jeremy Farrar, Nguyễn Văn Vĩnh Châu et al. · 2012 · New England Journal of Medicine · 1.7K citations
Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses
J. S. Mackenzie, Duane J. Gubler, Lyle R. Petersen · 2004 · Nature Medicine · 1.3K citations
Crimean-Congo haemorrhagic fever
Önder Ergönül · 2006 · The Lancet Infectious Diseases · 1.2K citations
Zika Virus
Lyle R. Petersen, Denise J. Jamieson, Ann M. Powers et al. · 2016 · New England Journal of Medicine · 1.2K citations
n 1947, a study of yellow fever yielded the first isolation of a new virus, from the blood of a sentinel rhesus macaque that had been placed in the Zika Forest of Uganda. 1 Zika virus remained in r...
Case Definitions, Diagnostic Algorithms, and Priorities in Encephalitis: Consensus Statement of the International Encephalitis Consortium
Arun Venkatesan, Allan R. Tunkel, Karen C. Bloch et al. · 2013 · Clinical Infectious Diseases · 1.1K citations
We anticipate that this document, representing a synthesis of our discussions and supported by literature, will serve as a practical aid to clinicians evaluating patients with suspected encephaliti...
Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans
Troy D. Querec, Rama Akondy, Eva K. Lee et al. · 2008 · Nature Immunology · 1.1K citations
Reading Guide
Foundational Papers
Start with Bhatt et al. (2013) for global burden (9770 citations), then Simmons et al. (2012) for clinical overview, and Capeding et al. (2014) for CYD-TDV trial data establishing field efficacy benchmarks.
Recent Advances
Pierson and Diamond (2020) reviews flavivirus threats; builds on Mackenzie et al. (2004) resurgence patterns.
Core Methods
Phase 3 randomized observer-masked trials (Capeding et al., 2014); seroprevalence stratification; VE calculation as 1 - (attack rate vaccine / attack rate placebo).
How PapersFlow Helps You Research Dengue Vaccine Development
Discover & Search
Research Agent uses searchPapers for 'tetravalent dengue vaccine phase 3 trials' to find Capeding et al. (2014), then citationGraph reveals 955 citing papers on ADE risks, and findSimilarPapers uncovers related efficacy studies like Simmons et al. (2012). exaSearch targets 'dengue vaccine serostatus efficacy' for rapid literature mapping.
Analyze & Verify
Analysis Agent applies readPaperContent to Capeding et al. (2014) abstract for trial data extraction, verifyResponse with CoVe checks ADE claims against Bhatt et al. (2013) burden stats, and runPythonAnalysis computes efficacy rates from trial tables using pandas. GRADE grading scores CYD-TDV evidence as high for seropositive cohorts.
Synthesize & Write
Synthesis Agent detects gaps in post-CYD-TDV candidates via contradiction flagging between Gubler (2011) urbanization trends and trial limits. Writing Agent uses latexEditText for manuscript sections, latexSyncCitations integrates Bhatt et al. (2013), and latexCompile generates polished reviews; exportMermaid visualizes serotype immunity diagrams.
Use Cases
"Analyze CYD-TDV efficacy by serostatus from phase 3 data"
Research Agent → searchPapers → Analysis Agent → readPaperContent (Capeding et al., 2014) → runPythonAnalysis (pandas plot of VE 56% seropositive vs hospitalization risks) → statistical output with p-values.
"Write review on dengue vaccine ADE risks with citations"
Synthesis Agent → gap detection → Writing Agent → latexEditText (intro on ADE) → latexSyncCitations (Simmons et al., 2012; Capeding et al., 2014) → latexCompile → PDF with formatted equations.
"Find code for dengue epidemiological modeling"
Research Agent → searchPapers ('dengue burden modeling') → paperExtractUrls (Bhatt et al., 2013 supplements) → paperFindGithubRepo → githubRepoInspect → runnable Python scripts for transmission simulations.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers (50+ dengue vaccine papers) → citationGraph → DeepScan (7-step verification of ADE claims from Capeding et al., 2014). Theorizer generates hypotheses on next-gen vaccines by synthesizing Gubler (2011) urbanization with trial data, outputting theory diagrams via exportMermaid. Chain-of-Verification ensures accuracy across flavivirus papers like Mackenzie et al. (2004).
Frequently Asked Questions
What defines dengue vaccine development?
It targets tetravalent vaccines for all four DENV serotypes, addressing ADE and cross-immunity (Simmons et al., 2012).
What are key methods in dengue vaccines?
Live-attenuated tetravalent like CYD-TDV tested in phase 3 randomized trials in endemic Asia (Capeding et al., 2014).
What are seminal papers?
Bhatt et al. (2013, 9770 citations) maps burden; Capeding et al. (2014, 955 citations) reports CYD-TDV efficacy.
What open problems persist?
ADE in seronegatives, durable cross-serotype protection, and trials in high-burden urban areas (Gubler, 2011).
Research Mosquito-borne diseases and control with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Dengue Vaccine Development with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers